Shikiar Asset Management Inc. Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Shikiar Asset Management Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 838 shares of the biopharmaceutical company’s stock after selling 1,070 shares during the period. Shikiar Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $736,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. FMR LLC raised its holdings in Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares during the period. Northern Trust Corp grew its position in Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after acquiring an additional 34,326 shares in the last quarter. Morgan Stanley grew its position in Regeneron Pharmaceuticals by 2.7% in the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after acquiring an additional 25,792 shares in the last quarter. Bank of New York Mellon Corp grew its position in Regeneron Pharmaceuticals by 0.3% in the third quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock valued at $796,142,000 after acquiring an additional 2,666 shares in the last quarter. Finally, Norges Bank acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $697,296,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,729 shares of company stock worth $13,124,641. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $2.83 during mid-day trading on Friday, reaching $896.82. The company’s stock had a trading volume of 507,466 shares, compared to its average volume of 412,356. The firm has a market cap of $98.43 billion, a price-to-earnings ratio of 25.81, a PEG ratio of 2.59 and a beta of 0.11. The business has a 50 day moving average price of $953.01 and a 200-day moving average price of $891.67. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the business posted $10.96 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on REGN shares. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. UBS Group increased their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays increased their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. Finally, Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $976.41.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.